Clinical analysis of Eravacycline in the treatment of patients with pulmonary and bloodstream infections caused by Multidrug-Resistant Acinetobacter baumannii

doi:10.3877/cma.j.issn.2096-1537.2025.10.15-0018

Abstract

Abstract:

Objective

To investigate the efficacy and safety of Eravacycline in the treatment of pulmonary infection combined with bloodstream infection caused by multidrug-resistant Acinetobacter baumannii.

Methods

A retrospective analysis was conducted on the clinical data of three patients admitted to the ICU of Wuhan Asia Heart General Hospital from February to August 2024. These patients had pulmonary infection and bloodstream infection caused by multidrug-resistant Acinetobacter baumannii. Biochemical indexes, bacterial culture and antimicrobial susceptibility test results, antimicrobial regimens, imaging data before and after treatment were collected to evaluate clinical efficacy and adverse drug reactions of patients.

Results

All three patients were male, aged 38-58 years. Acinetobacter baumannii was detected in bronchoalveolar lavage fluid and blood cultures, with susceptibility testing indicating resistance to carbapenem antibiotics. After treatment of Eravacycline, significant improvements were observed in clinical manifestations, inflammatory indicators, and imaging examinations. No Eravacycline-related adverse reactions were identified.

Conclusion

Eravacycline demonstrates favorable efficacy and safety in treating pulmonary infection combined with bloodstream infection caused by multidrug-resistant Acinetobacter baumannii.

Key words: Multidrug-resistant Acinetobacter baumannii, Pulmonary infection combined with bloodstream infection, Eravacycline

Xiaoyan Jiang, Jing Chen, bo Liu, Mingxiang Wu. Clinical analysis of Eravacycline in the treatment of patients with pulmonary and bloodstream infections caused by Multidrug-Resistant Acinetobacter baumannii[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), doi: 10.3877/cma.j.issn.2096-1537.2025.10.15-0018.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-1537.2025.10.15-0018

Figures/Tables 5

References 15

1	Zhanel GG, Cheung D, Adam H, et al. Review of Eravacycline, a novel Fluorocycline antibacterial agent [J]. Drugs, 2016, 76(5): 567-588.
2	Scott CJ, Zhu E, Jayakumar RA, et al. Efficacy of Eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii [J]. Ann Pharmacother, 2022, 56(12): 1299-1307.
3	Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel Fluorocycline antibiotic [J]. Antimicrob Agents Chemother, 2012, 56(5): 2559-2564.
4	Kunz Coyne, Ashlan J, Sara Alosaimy, et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022 [J]. Microbiol Spectr, 2024, 12(1): e0235123.
5	Alosaimy S, Morrisette T, Lagnf AM, et al. Clinical outcomes of Eravacycline in patients treated predominately for Carbapenem-resistant Acinetobacter baumannii [J]. Microbiol Spectr, 2022, 10(5): e0047922.
6	贾建超, 王奥钰, 张文平, 等. 依拉环素治疗碳青霉烯耐药鲍曼不动杆菌肺部感染效果观察 [J]. 中华实用诊断与治疗杂志, 2024, 38(10): 1057-1062.
7	Falcone M, Giordano C, Leonildi A, et al. Clinical features and outcomes of infections caused by metallo- β -lactamase–producing enterobacterales: a 3-year prospective study from an endemic area [J].Clin Infect Dis, 2024, 15: ciad725.
8	Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections [J]. N Engl J Med, 2014, 370(13): 1198-1208.
9	Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis [J]. Lancet Infect Dis, 2018, 18(3): 318-327.
10	Perez F, Hujer AM, Hujer KM, et al. Global challenge of multidrug-resistant Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2007, 51(10): 3471-3484.
11	Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections [J]. Clin Infect Dis, 2024, 7: ciae403.
12	Zeng M, Xia J, Zong Z, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by Carbapenem-resistant gram-negative bacilli [J]. J Microbiol Immunol Infect, 2023, 56(4): 653-671.
13	Alosaimy S, Molina KC, Bouchard J, et al. Early real-world evidence in the use of Eravacycline for the management of draconian infections [C]. Philadelphia, USA, 2020: 909539.
14	Jackson MN, Ortwine J, Wei W, et al. Combination Eravacycline therapy for Carbapenem resistant Acinetobacter baumannii pneumonia [J]. Open Forum Infect Dis, 2022, 9(2): 492-497.
15	Lunsted S, Molina KC, Barber GR, et al. Real world use of Eravacycline: a case series [C]. Las Vegas, NV , USA: ASHP Midyear Clinical Meeting & Exhibition, 2019.

抗生素	1号菌	2号菌	3号菌
美罗培南	≥16（R）	≥16（R）	≥16（R）
亚胺培南	≥16（R）	≥16（R）	≥16（R）
替加环素	4.0 （I）	≥8（R）	4.0（I）
米诺环素	8.0（I）	8.0（I）	4.0（S）
头孢哌酮/舒巴坦	≥64（R）	32.0（I）	≥64（R）
哌拉西林/他唑巴坦	≥128/4（R）	≥128/4（R）	≥128/4（R）

抗生素	1号菌	2号菌	3号菌
美罗培南	≥16（R）	≥16（R）	≥16（R）
亚胺培南	≥16（R）	≥16（R）	≥16（R）
替加环素	4.0 （I）	≥8（R）	4.0（I）
米诺环素	8.0（I）	8.0（I）	4.0（S）
头孢哌酮/舒巴坦	≥64（R）	32.0（I）	≥64（R）
哌拉西林/他唑巴坦	≥128/4（R）	≥128/4（R）	≥128/4（R）

患者		CRP（mg/L）	PCT（ng/ml）	WBC（（10⁹/L）	NEUT%	血培养/血NTS
病例1	治疗前	28.7	4.333	9.28	81.4	阳性
病例1	治疗后	64.9	2.98	9.2	69	阴性
病例2	治疗前	41.44	1.028	6.95	90.6	阳性
病例2	治疗后	3.71	0.366	5.05	67.9	阴性
病例3	治疗前	266.41	42.948	8.28	92.5	阳性
病例3	治疗后	30.37	6.673	7.63	82.5	阴性

患者		CRP（mg/L）	PCT（ng/ml）	WBC（（10⁹/L）	NEUT%	血培养/血NTS
病例1	治疗前	28.7	4.333	9.28	81.4	阳性
病例1	治疗后	64.9	2.98	9.2	69	阴性
病例2	治疗前	41.44	1.028	6.95	90.6	阳性
病例2	治疗后	3.71	0.366	5.05	67.9	阴性
病例3	治疗前	266.41	42.948	8.28	92.5	阳性
病例3	治疗后	30.37	6.673	7.63	82.5	阴性

患者		ALT（U/L）	AST（U/L）	总胆红素（μmol/L）
病例1	治疗前	20	-	22.7
	治疗后	8	-	13.7
病例2	治疗前	2361	3507	20.2
	治疗后	34	-	12.3
病例3	治疗前	11	-	42.4
	治疗后	8	-	27

Please choose a citation manager

Content to export